Evidence map›Paper›PMID 31173804›Full record

ArticlePreventive medicine2019

Prevalence and maternal characteristics associated with receipt of prenatal care provider counseling about medications safe to take during pregnancy.

Denise V D'Angelo, Brenda L Bauman, Cheryl S Broussard, Van T Tong, Jean Y Ko, Martha Kapaya, Leslie Harrison, Indu B Ahluwalia

Open access · greenAbstract read
In one paragraph

Article in Preventive medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Nicotine and the developing brain: Insights from preclinical models.Pharmacology, biochemistry, and behavior · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Denise V D'AngeloNational Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, United States of America. Electronic address: DDAngelo@cdc.gov.
Brenda L BaumanNational Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, United States of America.
Cheryl S BroussardNational Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, United States of America.
Van T TongNational Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, United States of America.
Jean Y KoNational Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, United States of America.
Martha KapayaNational Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, United States of America.
Leslie HarrisonNational Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, United States of America.
Indu B AhluwaliaNational Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, United States of America.
Centers for Disease Control and Prevention · USNational Center for Chronic Disease Prevention and Health Promotion · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

Use of some medications during pregnancy can be harmful to the developing fetus, and discussion of the risks and benefits with prenatal care providers can provide guidance to pregnant women. We used Pregnancy Risk Assessment Monitoring System data collected for 2015 births aggregated from 34 US states (n = 40,480 women) to estimate the prevalence of self-reported receipt of prenatal care provider counseling about medications safe to take during pregnancy. We examined associations between counseling and maternal characteristics using adjusted prevalence ratios (aPR). The prevalence of counseling on medications safe to take during pregnancy was 89.2% (95% confidence interval [CI]: 88.7-89.7). Women who were nulliparous versus multiparous (aPR 1.03; 95% CI: 1.02-1.04), who used prescription medications before pregnancy versus those who did not, (aPR 1.03; 95% CI: 1.02-1.05), and who reported having asthma before pregnancy versus those who did not, (aPR 1.05; 95% CI: 1.01-1.08) were more likely to report receipt of counseling. There was no difference in counseling for women with pre-pregnancy diabetes, hypertension, and/or depression compared to those without. Women who entered prenatal care after the first trimester were less likely to report receipt of counseling (aPR 0.93; 95% CI: 0.91-0.96). Overall, self-reported receipt of counseling was high, with some differences by maternal characteristics. Although effect estimates were small, it is important to ensure that information is available to prenatal care providers about medication safety during pregnancy, and that messages are communicated to women who are or might become pregnant.

Indexed as

CounselingHealth BehaviorPatient SafetyAdultFemaleHumansMaternal BehaviorPopulation SurveillancePregnancyPrenatal CarePrescription DrugsSelf ReportSocioeconomic FactorsPrescription DrugsMedication use during pregnancyPRAMSPregnancyPrenatal care counseling

Identifiers

PMID31173804
PMCPMC10985656
OpenAlexW2948636922

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.